Orexigen Therapeutics (OREX) 7.39 $OREX Today's Dead Cat

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 9:57 PM

Orexigen Therapeutics (OREX) 7.39 $OREX

Today's Dead Cat Bounce Stock: Orexigen Therapeutics (OREX)
at The Street - Wed Apr 22, 3:12PM CDT
Trade-Ideas LLC identified Orexigen Therapeutics (OREX) as a "dead cat bounce" (down big yesterday but up big today) candidate
OREX: 7.39 (+0.22)

Orexigen Faces Generic Challenge For Anti-Obesity Drug
Spencer Osborne - at Seeking Alpha - Wed Apr 22, 11:24AM CDT

OREX: 7.39 (+0.22), ACT: 295.22 (+0.69), VVUS: 2.50 (+0.04)

Novo's obesity drug will cost U.S. patients over $1,000 per month
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 9:52AM CDT

OREX: 7.39 (+0.22), NVO: 56.37 (-0.17), VVUS: 2.50 (+0.04), ARNA: 4.47 (+0.01)

Orexigen Announces Receipt of Paragraph IV Certification Notice
PR Newswire - Wed Apr 22, 6:30AM CDT
Orexigen Therapeutics, Inc. (NASDAQ: OREX) today announced that Orexigen and North American partner Takeda Pharmaceuticals have received notification of a Paragraph IV certification for certain patents for Contrave® (naltrexone HCl and bupropion HCl extended release) which are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. The certification resulted from the filing by Actavis Laboratories FL, Inc. of an Abbreviated New Drug Application (ANDA) challenging such patents for Contrave.
OREX: 7.39 (+0.22)

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Orexigen Therapeutics, Inc. and a Lead Plaintiff Deadline of May 11, 2015
Business Wire - Tue Apr 21, 9:39AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Orexigen Therapeutics, Inc. ("Orexigen" or the "Company"

(NASDAQ:OREX) securities between March 3, 2015 and March 5, 2015.
OREX: 7.39 (+0.22)

3 Promising Small-Caps Under $10 You Can Buy Right Now
Dan Caplinger, Selena Maranjian, and Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 21, 8:06AM CDT
The healthcare arena is a hotbed of interesting small-cap plays, including Orexigen Therapeutics, the maker of the obesity drug Contrave. Image: Orexigen Therapeutics. Many investors are afraid of investing in small-cap stocks, believing that the...
MBI: 9.34 (+0.04), OREX: 7.39 (+0.22), ARNA: 4.47 (+0.01)

Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Orexigen Therapeutics, Inc.
Business Wire - Mon Apr 20, 9:54AM CDT
Glancy Binkow & Goldberg LLP reminds investors in Orexigen Therapeutics, Inc. ("Orexigen" or the "Company"

(NASDAQ: OREX) who purchased the Company's securities between March 3 and March 5, 2015, inclusive (the "Class Period"

of the May 11, 2015 deadline to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
OREX: 7.39 (+0.22)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Orexigen Therapeutics, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of May 11, 2015 - OREX
PR Newswire - Wed Apr 15, 9:17AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
OREX: 7.39 (+0.22)

Don't Write Off Arena As Yet
Emerging Equities - at Seeking Alpha - Wed Apr 15, 7:33AM CDT

OREX: 7.39 (+0.22), PFE: 34.93 (+0.04), ARNA: 4.47 (+0.01)

3 Promising Healthcare Stocks Under $10
Keith Speights, The Motley Fool - Motley Fool - Wed Apr 15, 7:02AM CDT
Source: Wikipedia.org Stocks can be cheap and expensive at the same time. Novice investors might mistakenly think that a stock with a low share price is a bargain. However, some of these stocks are actually overpriced because their future...
OREX: 7.39 (+0.22), PACB: 5.90 (-0.07), VVUS: 2.50 (+0.04), ILMN: 190.04 (-9.27), ABBV: 64.52 (+0.91), ARNA: 4.47 (+0.01), OSUR: 6.75 (-0.03)

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Orexigen Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Tue Apr 14, 4:02PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf of purchasers of Orexigen Therapeutics, Inc. ("Orexigen" or the "Company"

(Nasdaq: OREX) securities during the period between March 3, 2015 and March 5, 2015, inclusive (the "Class Period"

. Investors who wish to become proactively involved in the litigation have until May 11, 2015 to seek appointment as lead plaintiff.
OREX: 7.39 (+0.22)

Vivus Sales Remain Flat - Stock Trend Not Good
Spencer Osborne - at Seeking Alpha - Mon Apr 13, 12:19PM CDT

OREX: 7.39 (+0.22), VVUS: 2.50 (+0.04), ARNA: 4.47 (+0.01)

Arena's 15,000 Scripts Set Pace Vs. Competitors
Spencer Osborne - at Seeking Alpha - Mon Apr 13, 10:00AM CDT

OREX: 7.39 (+0.22), ARNA: 4.47 (+0.01)

Law Offices of Howard G. Smith Reminds Investors of Orexigen Therapeutics, Inc. of the May 11, 2015 Deadline
Business Wire - Mon Apr 13, 9:30AM CDT
Law Offices of Howard G. Smith reminds investors who purchased Orexigen Therapeutics, Inc. ("Orexigen" or the "Company"

(NASDAQ:OREX) between March 3, 2015 and March 5, 2015, inclusive (the "Class Period"

of the May 11, 2015 lead plaintiff deadline. Investors are advised to contact the law firm to discuss their legal rights concerning the class action pending before the District Court for the Southern District of California.
OREX: 7.39 (+0.22)

Orexigen: Contrave Scripts Dip - Were My Concerns About Advertising Right?
Spencer Osborne - at Seeking Alpha - Mon Apr 13, 9:23AM CDT

OREX: 7.39 (+0.22), VVUS: 2.50 (+0.04), ARNA: 4.47 (+0.01)

The Best Stock to Invest in Obesity Drugs
Brian Orelli, The Motley Fool - Motley Fool - Sun Apr 12, 1:03PM CDT
Considering the limited number of obesity drugs, it seems easiest to pick the best stock in the field by process of elimination. Company Drug FDA Approved? Roche Xenical Yes VIVUS ...
ZFGN: 39.06 (+0.36), OREX: 7.39 (+0.22), NVO: 56.37 (-0.17), VVUS: 2.50 (+0.04), ARNA: 4.47 (+0.01)

OREXIGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Orexigen Therapeutics, Inc.
Business Wire - Fri Apr 10, 9:00PM CDT
Kahn Swick & Foti, LLC ("KSF"

and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 11, 2015 to file lead plaintiff applications in a securities class action lawsuit against Orexigen Therapeutics, Inc. (Nasdaq: OREX) if they purchased the Company's securities between March 3, 2015 and March 5, 2015, inclusive (the "Class Period"

. This action is pending in the United States District Court for the Southern District of California.
OREX: 7.39 (+0.22)

Orexigen Therapeutics to Speak at the Needham Healthcare Conference
PR Newswire - Fri Apr 10, 3:01PM CDT
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a corporate overview at the 2015 Needham Healthcare Conference in New York. The presentation is scheduled for Tuesday, April 14th at 12:50 p.m. Eastern Time. To listen to the live webcast or a replay of the discussion, please visit the Investors section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
OREX: 7.39 (+0.22)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Orexigen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OREX
PR Newswire - Fri Apr 10, 12:45PM CDT
Pomerantz LLP has filed a class action lawsuit against Orexigen Therapeutics, Inc. ("Orexigen" or the "Company"

(NASDAQ: OREX) and certain of its officers. The class action, filed in United States District Court, Southern District of California, is on behalf of a class consisting of all persons or entities who purchased Orexigen securities between March 3, 2015 and March 5, 2015, inclusive (the "Class Period"

. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act"

.
OREX: 7.39 (+0.22)

Arena's Partner Eisai Is Slashing Jobs - What Investors Need To Consider
Spencer Osborne - at Seeking Alpha - Fri Apr 10, 9:27AM CDT

OREX: 7.39 (+0.22), ARNA: 4.47 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

HiTHIUM Joins Cambridge to Boost Global Energy Storage

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

MV Transportation Celebrates Leadership Nomination for FTA

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Luvme Hair Offers Wig Variety for Winter Fashion

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

LaserAway Expands to 244 Clinics Over 20 Years

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Windward Bio Surges 68% in Nasdaq Debut

By Ryan Hughes Updated Nov 13, 2026 Category News Views 253

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...